No Data
*ST Pharmaceuticals: Report of Dali Pharmaceutical Co., Ltd. for the third quarter of 2024
Report for the third quarter of 2024 of Dali Pharmaceutical Co., Ltd.
2024 Semi-Annual Report of Dali Pharmaceutical Co., Ltd.
Summary of the 2024 semi-annual report of Dali Pharmaceutical Co., Ltd.
*Special Treat Da Yao (603963.SH): As of August 9, 2024, the company has 17,582 shareholders.
On August 13th, Gelunhui reported that as of August 9th, 2024, the number of shareholders in the company was 17,582.
On August 7, A-share lightning rod: Guangdong Tecsun Science & Technology - controlling shareholder and actual controller Guo Xiaobin plans to reduce shareholding by no more than 3.00%; Guangdong Highsun Group - Shenzhen Stock Exchange plans to terminate
Guangdong Tecsun Science & Technology's controlling shareholder and actual controller Guo Xiaobin intends to reduce his shareholding by no more than 3.00%; ST Dayoutan announced the termination of the planned change of control and resumed trading from August 7; Guangdong Highsun Group received a notification from the Shenzhen Stock Exchange to terminate the company's stock trading; Jiangyin Hengrun Heavy Industries' shareholder Cheng Lixin's holding of 4.72% of the shares was judicially frozen.
Capital Allocation Trends At Bomin Electronics (SHSE:603936) Aren't Ideal
